Orion Oyj - ESG Rating & Company Profile powered by AI
If you are employed by Orion Oyj and you wish to use your ESG aseessment, please contact us. This webpage of Orion Oyj was assembled by All Street Sevva using cutting edge Cognitive Robots. This Disclosure score includes seventeen United Nations Sustainable Development Goals including: 'Zero Hunger', 'Responsible Production & Consumption' and 'Peace, Justice & Strong Institutions'.
Orion Oyj in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.9; made up of an environmental score of 2.7, social score of 3.4 and governance score of 2.7.
2.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1336 | SyneuRx International (Taiwan) Corp | 3.0 | Medium |
| 1336 | Sensorion SA | 3.0 | Medium |
| 1353 | Orion Oyj | 2.9 | Medium |
| 1353 | Caribou Biosciences Inc | 2.9 | Medium |
| 1353 | Checkmate Pharmaceuticals Inc | 2.9 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Orion Oyj have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Orion Oyj disclose current and historical energy intensity?
Sign up for free to unlockDoes Orion Oyj report the average age of the workforce?
Sign up for free to unlockDoes Orion Oyj reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Orion Oyj disclose its ethnicity pay gap?
Sign up for free to unlockDoes Orion Oyj disclose cybersecurity risks?
Sign up for free to unlockDoes Orion Oyj offer flexible work?
Sign up for free to unlockDoes Orion Oyj have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Orion Oyj disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Orion Oyj conduct supply chain audits?
Sign up for free to unlockDoes Orion Oyj disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Orion Oyj conduct 360 degree staff reviews?
Sign up for free to unlockDoes Orion Oyj disclose the individual responsible for D&I?
Sign up for free to unlockDoes Orion Oyj disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Orion Oyj disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Orion Oyj disclose water use targets?
Sign up for free to unlockDoes Orion Oyj have careers partnerships with academic institutions?
Sign up for free to unlockDid Orion Oyj have a product recall in the last two years?
Sign up for free to unlockDoes Orion Oyj disclose incidents of discrimination?
Sign up for free to unlockDoes Orion Oyj allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Orion Oyj issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Orion Oyj disclose parental leave metrics?
Sign up for free to unlockDoes Orion Oyj disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Orion Oyj disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Orion Oyj disclose the pay ratio of women to men?
Sign up for free to unlockDoes Orion Oyj support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Orion Oyj disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Orion Oyj reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Orion Oyj involved in embryonic stem cell research?
Sign up for free to unlockDoes Orion Oyj disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Orion Oyj disclose its waste policy?
Sign up for free to unlockDoes Orion Oyj report according to TCFD requirements?
Sign up for free to unlockDoes Orion Oyj disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Orion Oyj disclose energy use targets?
Sign up for free to unlockDoes Orion Oyj disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Orion Oyj have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Orion Oyj
These potential risks are based on the size, segment and geographies of the company.
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.